STAT+: Novartis picks up experimental breast cancer therapy for $2B
Why it matters: This acquisition could lead to a more targeted and effective oral treatment for a common type of breast cancer.
- Novartis is investing $2 billion upfront, with an additional $1 billion possible, to acquire an experimental breast cancer drug.
- Synnovation Therapeutics is selling its oral medicine, SNV4818, which is in Phase 1/2 studies for HR-positive, HER2-negative breast cancer.
- SNV4818 is designed to specifically target a mutated PI3Kα enzyme, potentially offering a more precise treatment with fewer side effects by sparing healthy cells.
Novartis is acquiring an experimental breast cancer drug, SNV4818, from Synnovation Therapeutics for an upfront payment of $2 billion, with potential for an additional $1 billion based on milestones. This oral medicine, currently in early-stage trials, targets a mutated enzyme in HR-positive, HER2-negative breast cancer, aiming to improve treatment by selectively impacting cancer cells.
